Olema Pharmaceuticals UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Well, thank you, everyone. Good afternoon. Thank you for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research at UBS. Very happy to have on the stage with me the President and Chief Executive Officer of Olema Pharmaceuticals, Sean Bohen. Thank you for being here, Sean. It's a pleasure to see you.
Great to see you, Michael. Thank you for hosting us at this beautiful venue.
Absolutely. Talking about beautiful things, you guys have done some beautiful execution because you're executing across your phase III studies, put up a bunch of data over the last year. We've watched a lot of data. You've got KAT6. Talk about that too.
Obviously you've got some phase III data coming up in the first part of 2027.
That's right. Maybe we could just take a step back and you could offer us, and talk about and offer some opinions about the phase III OPERA-01 study for palazestrant in second-line metastatic breast cancer.
It's your first phase III study in a billion-dollar indication. I think it should work, but it's to the degree of how good does it work.
That's exactly right. So that investors can understand and have a better flavor for your drug versus the other SERD or CERAN or however you want to say it.
Talk to us about this phase III result and what you think is going to happen.
Yeah. So thank you again for the opportunity to talk about Olema. OPERA-02, or OPERA-01 is our first phase III, as you said. We have second one in the first-line setting, OPERA-02 ongoing, going well. OPERA-01 will read out in Q1 of next year. It is in the second, third line setting. It's a monotherapy palazestrant versus fulvestrant or exemestane, again, as a monotherapy with a progression-free survival primary endpoint. One of the interesting things about that particular indication is that it's really two populations.
molecularly defined. So, about 40% of the patients, the tumors harbor activating mutation in the ESR1 gene, the gene that encodes the estrogen receptor, which is the target of palazestrant. The remaining patients do not have that mutation, but all of these patients will have progressed on their CDK4/6 plus AI therapy. They have demonstrated endocrine resistance. If we go to the others in the SERD class, what has been shown, there have been a few that have demonstrated activity in that ESR1 mutant subset. So clearly estrogen receptor driven, you turn off this activated receptor, and you get some benefit in terms of controlling the disease. Much more difficult has been to get activity in the ESR1 wild-type subset.
where there have been efforts, but they have not succeeded. If we go back to our phase II data, we have compelling data in the ESR1 mutant subset. We have in a fairly similar population, 7.3 months of median progression-free survival. You expect two to three in the control arm. So, that would be a significant prolongation if you were able to duplicate that result in phase III. In the wild-type setting, we have 5.5 months, which is, again, if you were able to duplicate, would be significant and would be unique. So we see two ways in OPERA-01 to differentiate. One is success in the mutant and perhaps with better prolongation, or delay of progression, but prolongation of PFS. Then to have success that shows some benefit in the wild-type would be unique and would be there alone.
The mutant is a $2 billion a year market opportunity. The wild-type is about a $3 billion a year market opportunity. So these are significant on their own, but together would be really quite significant.
So let's unpack that a little bit. So in this phase III result, where you said approximately 40% would be mutant That's right and 60% wild-type.
We should start with the fact that other FDA-approved drugs, including Verzenio and Lilly, I think Yeah, imlunestrant, yeah have modest benefits, but statistically significant For sure.
Two-month benefits. That's right. on ESR1 mutants.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
